These innovative agents represent a significant progression in the management of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates promising efficacy in reducing blood glucose levels. https://fayfcrw980947.tblogz.com/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide-52284009